8-K: Mural Oncology Investor Day Highlights Late-Stage Clinical Trial Progress and IL-18 Program

Mural Oncology's Investor Day provided updates on late-stage clinical trials for nemvaleukin and plans for their IL-18 program, with key data readouts expected in 2025.

Summary

• Mural Oncology held its Investor Day on September 26, 2024, providing updates on its clinical programs.
• The company's lead candidate, nemvaleukin, is being evaluated in two potentially registrational trials.
• The ARTISTRY-7 trial for platinum-resistant ovarian cancer (PROC) has completed enrollment with 456 patients and expects an interim overall survival (OS) data readout in late Q1 or early Q2 2025.
• The ARTISTRY-6 trial for mucosal melanoma has completed enrollment with 92 patients and expects a top-line readout in Q2 2025.
• Mural plans to nominate a development candidate for its IL-18 program by the end of 2024 and submit an Investigational New Drug (IND) application to the FDA in Q4 2025.
• The company has a cash runway into Q4 2025.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with clear timelines for key milestones and data readouts. The company is progressing as expected with its clinical trials and preclinical programs. However, there are inherent risks associated with drug development, which temper the overall sentiment.

Positives

• Enrollment is complete for both the ARTISTRY-7 and ARTISTRY-6 trials.
• The company has a clear timeline for key data readouts in 2025.
• The IL-18 program is progressing with a planned IND submission in Q4 2025.
• Nemvaleukin has shown durable responses in prior trials, both as a monotherapy and in combination with pembrolizumab.
• Nemvaleukin has a manageable safety profile, allowing for outpatient administration.
• The company has received FDA Fast Track and Orphan Drug designations for nemvaleukin in mucosal melanoma.
• The company has a strong cash position to fund operations into Q4 2025.

Negatives

• The pembrolizumab monotherapy arm in the ARTISTRY-7 trial was closed due to futility.
• Regulatory filing for ARTISTRY-6 may be deferred if the ARTISTRY-7 study continues to final analysis.
• The company is reliant on the success of its clinical trials for future growth.

Risks

• Clinical trial results may not be positive or may not lead to regulatory approval.
• The company faces competition from other companies developing cancer therapies.
• There are inherent risks and uncertainties associated with drug development, including safety and efficacy concerns.
• The company's cash runway may not be sufficient to complete all planned activities.
• The FDA may make adverse decisions regarding the company's product candidates.

Future Outlook

Mural Oncology anticipates key data readouts from its ARTISTRY-7 and ARTISTRY-6 trials in 2025 and plans to advance its IL-18 program with an IND submission in Q4 2025. The company is also exploring potential accelerated approval pathways for its lead candidate, nemvaleukin.

Management Comments

• Caroline Loew, Ph.D., CEO of Mural Oncology, stated that they have a great deal of conviction around nemvaleukin and are pleased to share more details around their study designs and assumptions.
• The CEO also mentioned significant interest in their IL-18 program and the plan to submit an IND to the FDA in Q4 2025.
• Management believes these programs have the potential to be the next wave of much needed treatment options for cancer patients.

Industry Context

This announcement is relevant to the immuno-oncology space, where there is a high demand for novel therapies, particularly for cancers with limited treatment options like platinum-resistant ovarian cancer and mucosal melanoma. The company's focus on engineered cytokines aligns with the broader industry trend of developing more targeted and effective immunotherapies.

Comparison to Industry Standards

• The ARTISTRY-7 trial's design is benchmarked against prior phase 3 trials in platinum-resistant ovarian cancer, which had median overall survival (OS) on the chemotherapy control arm between 8 and 13 months, while Mural's trial assumes 10 months.
• The ARTISTRY-6 trial's target response rate of 25% is compared to historical data in mucosal melanoma, where single-agent checkpoint inhibitors have shown response rates of 10-15%.
• The company's engineered IL-18 program is designed to overcome the limitations of native IL-18, which is rapidly cleared from circulation and neutralized by IL-18 binding protein (IL-18BP).
• The company's approach to engineering IL-2 with nemvaleukin is designed to mitigate the toxicities associated with high-dose IL-2, which is a known treatment for melanoma and renal cell carcinoma but is limited by its toxicity profile.

Stakeholder Impact

• Shareholders can expect updates on clinical trial progress and potential regulatory filings in 2025.
• Patients with platinum-resistant ovarian cancer and mucosal melanoma may benefit from new treatment options if the clinical trials are successful.
• Employees are working on advancing the company's clinical programs and preclinical research.
• The company's success could lead to new partnerships and collaborations with other companies and research institutions.

Next Steps

• Mural will continue to monitor the ARTISTRY-7 trial for overall survival events and expects an interim analysis readout in late Q1 or early Q2 2025.
• The company will prepare for the top-line data readout of the ARTISTRY-6 trial in Q2 2025.
• Mural will nominate a development candidate for its IL-18 program by the end of 2024.
• The company plans to submit an IND application for its IL-18 program in Q4 2025.
• Mural will continue discussions with the FDA regarding potential accelerated approval pathways for nemvaleukin.

Key Dates

Keywords

nemvaleukin, IL-18, immunotherapy, cancer, clinical trials, ovarian cancer, mucosal melanoma, cytokine, ARTISTRY-7, ARTISTRY-6, FDA, biologics license application